Use of primate IFN-gamma binding molecules
OwnerMarie-Ange Buyse, Katrien Lorreinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to the therapeutic use of molecules which bind and neutralize IFN-γ in primates. More specifically, the present invention relates to the use of an anti-primate IFN-γ antibody for preventing or treating diseases wherein IFN-γ is pathogenic. The present invention further relates to a pharmaceutical composition comprising the anti-primate IFN-γ antibody D9D10 for preventing or treating pathological reactions caused by IFN-γ.
Claims11
Use of an anti-primate IFN-γ molecule for the manufacture of a pharmaceutical composition for preventing or treating pathological reactions caused by IFN-γ in a primate.
Use of an anti-primate IFN-γ molecule for the manufacture of a pharmaceutical composition for preventing or treating sepsis or septic shock in a primate.
A method for preventing or treating pathological reactions caused by IFN-γ in a primate, comprising administering a pharmaceutical effective amount of an anti-primate IFN-γ molecule.
A method for preventing or treating sepsis or septic shock in a primate, comprising administering a pharmaceutical effective amount of an anti-primate IFN-γ molecule.
A pharmaceutical composition comprising an anti-primate IFN-γ molecule in an amount effective in the prevention or treatment of pathological reactions caused by IFN-γ in a primate.
Dependencies are inferred from the claim text.